Oakland A’s exec believes AI, health tech will transform pro sports

Oakland A’s general manager Billy Beane predicts health technology and AI will transform professional baseball and sports, according to a report by CNBC.

In an interview with the news organization, Beane stated professional sports teams are already using devices and data-driven techniques to track the health of players and minimize injuries. However, he said challenges with data privacy laws sometimes prevent teams from getting access to a player’s health history.   

Additionally, Beane said AI is “poised to transform the business of baseball" and other sports with recruiting. Though the Oakland A’s aren’t using AI for scouting, he said it will soon be used to help teams recruit the next professional players.

"One of the reasons we haven't been more aggressive with using AI is because we don't have the money," Beane told CNBC. "That's almost a venture project for a business like ours. It might be a five-year, six-year project. And it could turn into nothing, you know, when it's all said and done. That's the challenge of being with a small business in our space. We don't have the ability to do sort of those venture projects internally. We need to make sure that every dollar we spend we get some return which is not a perfect world."

To read the full report, click the link below.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.